title: [New oral anticoagulants in patients with atrial fibrillation: efficacy and safety data from the real world].
abstract: New oral anticoagulants (NOACs: dabigatran, rivaroxaban, apixaban and edoxaban) proved to be at least non-inferior to warfarin in reducing thromboembolic risk in patients with atrial fibrillation. In addition, NOACs have been demonstrated to be safe and associated with a significant reduction in major and intracranial bleeding events. With the exception of apixaban, an increase in gastrointestinal bleedings has been observed, but as a whole NOACs have been shown to reduce mortality with rates similar to those of warfarin.Currently, NOACs are spreading slowly into clinical practice because of fears among clinicians and regulatory limitations to their prescription. However, efficacy and safety of NOACs have been confirmed by real-world data, also in elderly and frail patients, who represent the majority of treated subjects. Edoxaban has recently been approved by the Food and Drug Administration and the European Medicines Agency and marketed from some months. Real-world data are expected shortly. The large body of evidence in support of NOAC efficacy and safety should lead to an increased use of these new drugs in patients affected by atrial fibrillation.
authors.affiliation: U.O.C. Cardiologia, Ospedale Maggiore, Azienda USL di Bologna, Bologna.
authors.forename: Letizia
authors.initials: L
authors.lastname: Riva
authors.affiliation: U.O.C. Cardiologia, Ospedale Maggiore, Azienda USL di Bologna, Bologna.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Di Pasquale
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D001281:Atrial Fibrillation / Q000150:complications; D000069604:Dabigatran / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D011720:Pyrazoles / Q000008:administration & dosage / Q000009:adverse effects; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects; D011728:Pyridones / Q000008:administration & dosage / Q000009:adverse effects; D012042:Registries; D000069552:Rivaroxaban / Q000008:administration & dosage / Q000009:adverse effects; D013844:Thiazoles / Q000008:administration & dosage / Q000009:adverse effects; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D011720:Pyrazoles; D011725:Pyridines; D011728:Pyridones; D013844:Thiazoles; C522181:apixaban; D000069552:Rivaroxaban; D000069604:Dabigatran; C552171:edoxaban